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Abstract
Disease progression modeling (DPM) of Alzheimer’s disease (AD) aims at re-
vealing long term pathological trajectories from short term clinical data. Along
with the ability of providing a data-driven description of the natural evolution of
the pathology, DPM has the potential of representing a valuable clinical instru-
ment for automatic diagnosis, by explicitly describing the biomarker transition
from normal to pathological stages along the disease time axis. In this work
we reformulated DPM within a probabilistic setting to quantify the diagnostic
uncertainty of individual disease severity in an hypothetical clinical scenario,
with respect to missing measurements, biomarkers, and follow-up information.
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We show that the staging provided by the model on 582 amyloid positive testing
individuals has high face validity with respect to the clinical diagnosis. Using
follow-up measurements largely reduces the prediction uncertainties, while the
transition from normal to pathological stages is mostly associated with the in-
crease of brain hypo-metabolism, temporal atrophy, and worsening of clinical
scores. The proposed formulation of DPM provides a statistical reference for
the accurate probabilistic assessment of the pathological stage of de-novo indi-
viduals, and represents a valuable instrument for quantifying the variability and
the diagnostic value of biomarkers across disease stages.
Keywords: Alzheimer’s disease, Diagnosis, Disease progression modeling,
Gaussian process, Clinical trials
2
1. Introduction
Neurodegenerative disorders (NDDs), such as Alzheimer’s disease (AD), are
characterised by the progressive pathological alteration of the brain’s biochemi-
cal processes and morphology, and ultimately lead to the irreversible impairment
of cognitive functions [1]. The correct understanding of the relationship between5
the different pathological features is of paramount importance for improving the
identification of pathological changes in patients, and for better treatment [2].
To this end, ongoing research efforts aim at developing precise models al-
lowing optimal sets of measurements (and combinations of them) to uniquely
identify pathological traits in patients. This problem requires the definition of10
optimal ways to integrate and jointly analyze the heterogeneous multi-modal
information available to clinicians [3, 4, 5]. By consistently analyzing multi-
ple biomarkers that to date have mostly been considered separately, we aim
at providing a richer description of the pathological mechanisms and a better
understanding of individual disease progressions.15
Disease progression modeling (DPM) is a relatively new research direction
for the study of NDD data [6, 7, 8, 9, 10, 11, 12, 13]. The main goal of DPM
consists in revealing the natural history of a disorder from collections of imag-
ing and clinical data by: 1) quantifying the dynamics of NDDs along with
the related temporal relationship between different biomarkers, and 2) staging20
patients based on individual observations for diagnostic and interventional pur-
poses. Therefore, this research domain is closely related to the exploitation
of advanced statistical/machine-learning approaches for the joint modelling of
the heterogeneous and information available to clinicians: imaging, biochemical,
and clinical biomarkers. Differently from the several predictive machine-learning25
approaches proposed in the past in NDD research, disease progression models
aim at explicitly estimating the temporal progression of the biomarkers from
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normal to pathological stages, to provide a better interpretation and under-
standing of the natural evolution of the pathology. For this reason it represents
a very appealing modeling approach in clinical settings.30
The main challenge addressed by DPM consists in the general lack a well-
defined temporal reference in longitudinal clinical dataset of NDDs. Indeed, age
or visit date information are biased time references for the individual longitudi-
nal measurements, since the onset of the pathology may vary across individuals
according to genetic and environmental factors [14]. This is a very specific35
methodological issue requiring the extension and generalization of the analysis
approaches classically used in time-series analysis.
To tackle this problem, it is usually assumed that individual biomarkers are
measured relatively to an underlying disease trajectory defined with respect to
an absolute time axis describing the natural history of the pathology [7]. Each40
individual is thus characterized by a specific observation time that needs to
be estimated in order to assess the individual pathological stage. According
to this statistical setting, we therefore aim at estimating a group-wise disease
model defined with respect to an absolute time scale, along with individual
time re-parameterisation relative to the group-wise progression. This modeling45
paradigm has been implemented in a number of approaches proposed in the
recent years, either by assuming continuous temporal trajectories of the bio-
markers [7, 8, 9, 10, 11, 12, 13], or by modeling the disease progression as a
sequence of discrete events [6, 15].
For example, in [8] the authors proposed to model the temporal biomarker50
trajectories through random effect regression, building on the theory of self-
modeling regression [16], while the authors of [11] re-frame the random effect
regression model in a geometrical setting, based on the assumption of a logistic
curve shape for the average biomarker trajectories.
4
Continuous progression models have been recently extended to the modelling55
of brain images based on the time-reparameterization of voxel/mesh-based mea-
sures [9, 10, 13].
The use of disease progression models for diagnostic purposes is instead less
investigated. Predictive models of patient staging were proposed within the
setting of the Event Based Model [6], or still through random effect modeling60
[12]. However, the Event Based Model relies on the coarse binary discretization
of the biomarker changes, and does not account for longitudinal observations,
while the predictive models proposed in [12] and [17] require cohorts with known
disease onset, and therefore lack flexibility while being prone to bias due to mis-
diagnosis and uncertainty of the conversion time.65
Furthermore, these methods are generally not formulated in a probabilis-
tic setting, which makes it difficult to account for uncertainties in biomarker
progressions and diagnostic predictions. Indeed, the quantification of the vari-
ability associated with the biomarkers trajectories, as well as the assessment
of the diagnostic uncertainty in de-novo patients, are crucial requirements for70
decision making in clinical practice [18].
Nonetheless, the ensemble of this research offers a sight of the potential of
these approaches in representing a novel and powerful diagnostic instrument: in
this study we thus aim at assessing the ability of DPM in providing a statistical
reference for the transition from normal to pathological stages, for probabilistic75
diagnosis in the clinical scenario. To this end, we reformulate classical DPM
within a Bayesian setting in order to allow the probabilistic estimate of the
biomarker trajectories and the quantification of the uncertainty of predictions
of the individual pathological stage. The resulting probabilistic framework is
exploited in an hypothetical clinical scenario, for the estimation of the patholog-80
ical stage in a de-novo cohort of testing individuals, by assessing the influence
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of missing observations, biomarkers, and follow-up information.
The manuscript is structured as follows. Section 2.1 formulates DPM based
on Bayesian Gaussian Process regression [19], while Section 2.2 illustrates the
validation of our model on clinical and multivariate imaging measurements from85
a cohort of 782 amyloid positive individuals extracted from the ADNI database.
2. Methods
2.1. Statistical setting
This section highlights the statistical framework employed in this study,
based on the reformulation of self-modeling regression withing a Bayesian set-90
ting. This achieved by 1) defining a random effect Gaussian process regression
model to account for individual correlated time series (section 2.1); 2) modeling
individual time transformations encoding the information on the latent patho-
logical stage (section 2.1.2); and 3) introducing a monotonicity information in
order to impose a regular behaviour on the biomarkers trajectories (section95
2.1.3). We finally illustrate in section 2.1.4 how the proposed framework leads
to a probabilistic model of disease staging in de-novo individuals, naturally ac-
counting for missing information. Further details on model specification and
inference are provided in the Supplementary Section AppendixA.1, while the
experimental validation on synthetic data is reported in Supplementary Section100
AppendixA.2.
2.1.1. Gaussian process-based random effect modeling of longitudinal progres-
sions
In what follows, longitudinal measurements of Nb biomarkers {b1, . . . , bNb}
over time are given for N individuals.105
We represent the longitudinal biomarker’s measures associated with each
individual j as a multidimensional array (yj(t1),yj(t2), . . . ,yj(tkj ))> sampled
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at kj multiple time points t = {t1, t2, . . . , tkj}. Although different biomarkers
may be in reality sampled at different time-points, for the sake of notation
simplicity in what follows we will assume, without loss of generality, that the110
sampling time is common among them. The observations for individual j at
a single time point t are thus a random sample from the following generative
model:
yj(t) =
(
yjb1(t), y
j
b2
(t), . . . , yjbNb
(t)
)>
(1)
= f(t) + νj(t) + ε, (2)
where f(t) = (fb1(t), fb2(t) . . . , fbNb (t))
> is the fixed effect function modelling
the biomarker’s longitudinal evolution, νj(t) = (νjb1(t), ν
j
b2
(t), . . . , νjbNb
(t))> is115
the individual random effect, and ε = (εb1 , εb2 , . . . , εbNb )
> is time-independent
observational noise. The group-wise evolution is modelled as a GP, f ∼ GP(0,ΣG),
the individual random effects are assumed to be correlated perturbations νj ∼
N (0,ΣS), while the observational noise is assumed to be a Gaussian heteroskedas-
tic term ε ∼ N (0,Σε), where Σε is a diagonal matrix diag[σ2b1,σ2b2, . . . ,σ2bNb ].120
Fixed Effect Process
The covariance function ΣG describes the biomarkers temporal variabil-
ity, and is represented as a block-diagonal matrix ΣG(f , f) = diag[Σb1(fb1 ,
fb1),Σb2(fb2 , fb2), . . . ,ΣbNb (fbNb , fbNb )], where each block represents the within-
biomarker temporal covariance expressed as a negative squared exponential125
function Σb(fb(t1), fb(t2)) = ηb exp
(
− (t1−t2)
2
2 l2b
)
, and where the parameters ηb
and lb are the marginal variance and length-scale of the biomarker’s temporal
evolution, respectively.
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Individual Random Effects
The random covariance function ΣS models the individual deviation from130
the fixed effect, and is represented as a block-diagonal matrix ΣS(νj ,νj) =
diag[ Σjb1(ν
j
b1
, νjb1),Σ
j
b2
(νjb2 ,ν
j
b2
), . . . ,ΣbjNb
(νjbNb
,νjbNb
)], where each block Σjb
corresponds to the covariance function associated with the individual process
νjb(t). Thanks to the flexibility of the proposed generative model, any form of
the random effect covariance ΣS can be easily specified in order to model the135
subject-specific biomarkers’ progression. In what follows we will use a linear
covariance form Σjb(ν
j
b(t1),ν
j
b(t2)) = (σ
j
b)
2
(
(t1 − t)(t2 − t)
)
, where t is the av-
erage observational time for individual j, when more than 4 measurements are
available, and i.i.d. Gaussian covariance form Σjb(ν
j
b(t1),ν
j
b(t2)) = (σ
j
b)
2 when
2 or 3 measurements are available, while assigning it to 0 otherwise (thus by140
accounting only for the observational noise σ2b). This choice is motivated by
stability concerns, in order to keep the model complexity compatible with the
generally limited number of measurements available for each individual.
2.1.2. Individual time transformation
The generative model (1) is based on the key assumption that the longitu-145
dinal observations across different individuals are defined with respect to the
same temporal reference. This assumption may be invalid when the temporal
alignment of the individual observations with respect to the common group-wise
model is unknown, for instance in the typical scenario of a clinical trial in AD
where the patients’ observational time is relative to the common baseline, and150
where the disease onset is a latent event (past or future) which is not directly
measurable. This modeling aspect is integrated by assuming that each individ-
ual measurement is made with respect to an absolute time-frame τ through a
time-warping function t = φj(τ) that models the time-reparameterization with
respect to the common group-wise evolution. Model (1) can thus be reparame-155
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terized as
yj(φj(τ)) = f(φj(τ)) + νj(φj(τ)) + ε. (3)
The present formulation allows the specification of any kind of time transfor-
mation, and in what follows we shall focus on the modelling of a linear reparam-
eterization of the observational time φj(τ) = τ + dj . This modeling assumption
is mostly motivated by the choice of working with a reasonably limited number160
of parameters, compatibly with the generally short follow-up time available per
individual (cfr. Table 2). Within this setting, the time-shift dj encodes the
disease stage associated with the individual relatively to the group-wise model.
2.1.3. Monotonic constraint in random-effect multimodal GP regression
Due to the non-parametric nature of Gaussian process regression, we need an165
additional constraint on model (3) in order to identify a unique solution for the
time transformation. By assuming a steady temporal evolution of biomarkers
from normal to pathological values, we shall assume that the biomarker trajec-
tories described by (3) follow a (quasi) monotonic behaviour. This requirement
can be implemented by imposing a prior positivity constraint on the derivatives170
of the GP function. Inspired by [20], we impose a monotonicity constraint by
assuming a probit-likelihood for the derivative measurements m(t) associated
with the derivative process ḟ(t) = df(t)dt at time t:
p(m(t)|ḟ(t)) = Φ
(
1
λ
ḟ(t)
)
, (4)
with Φ(z) =
∫ z
−∞N (x|0, 1) dx. The quantity λ > 0 is an additional model
parameter controlling the degree of positivity enforced on the derivative process,175
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with values approaching zero for stronger monotonicity constraint. In what
follows, the monotonicity of each biomarker is controlled by placing 10 derivative
points equally spaced on the observation domain, and by fixing the Nb derivative
parameters {λbk}
Nb
k=1 to the value of 1e-6. The position of the derivative points
was updated at each iteration, according to the changes of the GP domain.180
By following a similar construction, we could equally enforce a monotonic
behavior to the random effects associated with the individual trajectories. This
additional constraint would however come with a cumbersome increase of the
model complexity, since it would introduce an additional layer of virtual deriva-
tive parameters (with associated location) per individual. Moreover, while we185
are interested in modeling a globally monotonic biomarker trajectory on the
fixed parameters, we relax this constraint at the individual level, since some
subjects may be characterised by non strictly monotonic time-series due to spe-
cific clinical conditions.
Model likelihood and parameters190
Given the sets of individual biomarker measurements y = {(yj(ti))k
j
i=1}Nj=1,
and of D control derivatives m = {mbk(t′l)}Dl=1 at points t′ = {t′l}Dl=1 for the
progression of each biomarker bk, the random effect GP model posterior is:
p
(
f , ḟ ,νj |y,m
)
=
1
Z
p(f , ḟ |t, t′)p(ν|t)p(y|f ,ν)p(m|ḟ)
= p(f , ḟ |t, t′)p(ν|t)p(y|f ,ν)∏
k
∏
l
Φ
(
1
λ
ḟbk(t
′
l)
)
, (5)
where ν = {νj}Nj=1. Due to the non-Gaussianity of the derivative term Φ, the
direct inference on the posterior is not possible due to its analytically intractable195
form. For this reason, we employ an approximate inference scheme based on
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classical approaches to Gaussian process with binary activation functions [21]
(AppendixA.1).
Overall, model (3) is identified by (Nj + 3)Nb +Nj parameters, represented
by the fixed effects and noise θG = {ηbk , lbk , εbk}
Nb
k=1, by the individual random200
effects parameters θjG = {σ
j
bk
}Nbk=1 and by the time-shifts dj .
In what follows, the optimal parameters are obtained by maximising the ap-
proximated log-marginal likelihood derived from the posterior (5) through conju-
gate gradient descent, via alternate optimization between the hyper-parameters
θG and θ
j
G, and the individuals’ time-shifts d
j . Regularization is also enforced205
by introducing Gaussian priors for the parameters θG and θ
j
G.
2.1.4. Prediction of observations and individual staging
Gaussian processes naturally allow for probabilistic predictions given the
observed data. At any given time point t∗, the posterior biomarker distribution
has the Gaussian form p(f∗|t∗,y, t,m, t′) ∼ N (f∗|µ∗,Σ∗):210
µ∗ = ΣG(f(t
∗), f(t))(Σjoint + Σ̃joint)
−1µ̃joint (6)
Σ∗ = ΣG(f(t
∗), f(t∗))− ΣG(f(t∗), f(t))
(Σjoint + Σ̃joint)
−1ΣG(f(t), f(t
∗)), (7)
where the matrix
(
Σjoint + Σ̃joint
)
is the joint covariance resulting from the
inference scheme detailed in Supplementary Section AppendixA.1 [20].
We also derive a probabilistic model for the individual temporal staging
given a set of biomarker observations y∗, thanks to the Bayes formula:
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p(t∗|y∗,y, t,m, t′) = p(y∗|t∗,y, t,m, t′)
p(t∗)/p(y∗|y, t,m, t′), (8)
which we compute by assuming an uniform distribution on t∗, and by noting215
that p(y∗|t∗,y, t,m, t′) ∼ N (µ∗,Σ∗ + Σε). In particular, the covariance form
ΣG(f(t
∗), f(t∗)) can be specified in order to account for incomplete data, and
thus generalizes the GP model for predictions in presence of missing biomarker
observations. The posterior distribution (8) quantifies the confidence of the
model about the individual disease staging, and thus is a valuable information220
about the precision of the diagnosis. We will also compute the expectation of
the distribution p(t∗|y∗,y, t,m, t′), which provides a scalar value that can be
used in subsequent classification methods.
2.2. Meterials and Methods
2.2.1. Study Participants225
Data used in the preparation of this article were obtained from the ADNI
database (http://adni.loni.usc.edu). The ADNI was launched in 2003 as
a public-private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial magnetic res-
onance imaging, positron emission tomography, other biological markers, and230
clinical and neuropsychological assessment can be combined to measure the pro-
gression of MCI and early AD. For up-to-date information, see www.adni-info.
org.
2.2.2. Data Processing
We collected longitudinal measurements for the ADNI individuals with base-235
line values of cerebrospinal fluid (CSF) Aβ amyloid lower than the nominal val-
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Group NL NL converted MCI stable MCI converted AD
Training data
N 67 5 0 53 75
Age 73 (6) 81.4 (5.2) / 72 (7.7) 73 (8.5)
Sex (% females) 61 0 / 43 45
Education (yrs) 16.2 (2) 17.2 (3) / 15.8 (2.6) 16 (2.4)
ADAS13 8.8 (4.5) 13.8 (2.4) / 22.6 (6.7) 31.3 (8.5)
FAQ 0.2 (0.6) 0.4 (0.5) / 5.2 (4.5) 12.9 (7)
RAVLT learning 5.6 (2.6) 2.2 (1.9) / 3.2 (2.5) 1.8 (1.7)
Entorhinal (cm3) 3.9 (0.6) 3.7 (0.5) / 3.2 (0.7) 2.9 (0.6)
Hippocampus (cm3) 7.5 (0.9) 6.7 (0.7) / 6.2 (0.9) 6 (9.3)
Ventricles (cm3) 36 (20) 57 (26) / 42 (21) 47 (22)
Whole brain (cm3) 1057 (105) 1106 (116) / 1040 (107) 1013 (113)
FDG 6.6 (0.5) 6.1 (0.65) / 5.7 (0.6) 5.2 (0.64)
AV45 1.2 (0.2) 1.3 (0.09) / 1.4 (0.2) 1.4 (0.2)
Testing data
N 74 17 243 106 145
Age 75.3 (5.9) 76.5 (4) 73.3 (7) 73.6 (7.3) 75 (7.9)
Sex (% females) 55 41 39 40 39
Education (yrs) 16 (2.9) 16.2 (2.6) 16 (2.8) 16 (3) 15.3 (3.1)
ADAS13 9.8 (4) 11.7 (3.4) 15.7 (6) 21 (6.1) 29.4 (8.2)
FAQ 0.5 (1.3) 0.6 (1.6) 2.7 (3.5) 5.1 (4.7) 12.9 (6.8)
RAVLT learning 5.6 (2.2) 5.6 (2.7) 4.3 (2.5) 2.8 (2.2) 1.8 (1.9)
Entorhinal (cm3) 3.8 (0.4) 3.6 (0.7) 3.6 (0.7) 3.1 (0.7) 2.7 (0.7)
Hippocampus (cm3) 7.2 (0.7) 7.2 (0.8) 6.9 (1) 6 (0.8) 5.7 (0.1)
Ventricles (cm3) 33 (15) 44 (21) 39 (23) 41 (23) 49 (24)
Whole brain (cm3) 1019 (102) 1055 (93) 1056 (100) 992 (110) 972 (124)
FDG 6.5 (0.62) 6.4 (0.7) 6.3 (0.7) 5.9 (0.6) 5.4 (0.7)
AV45 1.21 (0.19) 1.4 (0.2) 1.3 (0.19) 1.4 (0.2) 1.4 (0.2)
Table 1: Baseline sociodemographic and clinical information for training and testing study
cohort. NL: normal individuals, MCI: mild cognitive impairment, AD: Alzheimer’s patients.
ADAS13: Alzheimer’s Disease Assessment Scale-cognitive subscale, 13 items; FAQ: Functional
Assessment Questionnaire; RAVLT learning: Rey Auditory Verbal Learning Test, learning
item; FDG: (18)F-fluorodeoxyglucose positron emission tomography (PET) imaging; AV45:
(18)F-florbetapir Amyvid PET imaging.
ues of 192 pg/ml. The information was extracted from the ADNIMERGE1 R
package[22] (MEDIAN field of the upennbiomk_master table). This prelim-
inary selection is aimed to validate the model on a clinical population likely to
represent the whole disease time-span.240
The model was trained on a group of 200 randomly selected individuals in-
cluding healthy volunteers, mild cognitive impairment subjects converted to AD
(MCI conv), and AD patients having at least one measurement for each of the
1adni.bitbucket.io/adnimerge.html
13
following biomarkers: volumetric measures (hippocampal, ventricular, entorhi-
nal, and whole brain volumes), glucose metabolism (average normalized FDG245
uptake in prefrontal cortex, anterior cingulate, precuneus and parietal cortex),
brain amyloidosys (average normalized AV45 uptake in frontal cortex, anterior
cingulate, precuneus and parietal cortex), and functional, neuropsychological
and cognitive function measured by common scores (ADAS13, RAVLT learn-
ing, and FAQ)2. The testing set was composed of the remaining 582 subjects,250
including a subgroup of MCI non converted to AD during the observational
time (MCI stable). The image-derived measures used in the study (volumet-
ric MRI and average uptake values for AV45- and FDG-PET) were the scalar
estimates reported in the ADNIMERGE package (adnimerge table). The vol-
umetric measures were scaled by the individual total intracranial volume, and255
all the biomarkers measurements were converted into quantile scores (0 to 1 for
normal to abnormal values), with respect to the biomarkers distribution of the
training set. This latter modeling precaution is aimed to avoid spurious corre-
lation between training and testing data due to the combined normalization of
the values.260
The modeling results were evaluated with respect to the baseline diagnostic
information reported in the ADNI database, assessed according to the WMS and
NINCDS/ADRDA AD criteria [23]. Conversion to MCI or AD was established
according to the last follow-up information. Moreover, the MCI group was
composed by 138 individuals with baseline diagnosis of early MCI, assessed265
through the Wechsler Memory Scale Logical Memory II. Among these subjects,
14 of them were in the training group (26% of the total MCI training set size),
2ADAS13: Alzheimer’s Disease Assessment Scale-cognitive subscale, 13 items; FAQ: Func-
tional Assessment Questionnaire; RAVLT learning: Rey Auditory Verbal Learning Test,
learning item; FDG: (18)F-fluorodeoxyglucose positron emission tomography (PET) imag-
ing; AV45: (18)F-florbetapir Amyvid PET imaging.
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while the remaining 124 were in the testing set (35% of the total MCI testing
set size).
Table 1 shows baseline clinical and sociodemographic information of the270
individuals used respectively in training and testing set, while in Table 2 we
report the average follow-up time and the ratio of missing data of the pooled
sample. Supplementary Section AppendixA.2.6 reports the R code used for data
pre-processing.
2.3. Longitudinal modelling of Alzheimer’s disease progression275
2.3.1. Model training
The model was applied in order to estimate the temporal biomarker evolution
and the disease stage associated with each individual in the training set. The
plausibility of the model was assessed by group-wise comparison of the predicted
time-shift, and by correlation with respect to the time to AD diagnosis for the280
MCI individuals subsequently converted to AD. For sake of comparison we also
correlated the progression modelled with our approach with respect to the one
estimated with the method proposed in [8]. The method was applied to the
training data by using the standard parameters defined in the R package grace3
(see Supplementary Material AppendixA.2.2 for further details).285
3https://mdonohue.bitbucket.io/grace/
Ventr Hippo Ent Whole Brain ADAS13 FAQ RAVLT AV45 FDG
Training data
2.3 (0) 2.3 (0) 2.3 (0) 2.3 (0) 3 (0) 3.3 (0) 3.3 (0) 1.9 (0) 1.6 (0)
Testing data
3.4 (11) 3.4 (11) 3.4 (11) 3.4 (11) 3.9 (0) 3.9 (0) 3.9 (0) 3.8 (43) 3 (19)
Table 2: Average follow-up years and percentage of individuals with missing data (in paren-
thesis).
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Figure 1: A) Modelled biomarker progression in the training set of 200 Aβ amyloid positive
individuals (solid/dashed lines: mean ± sd). B) Posterior prediction for the individual time
shift in training data (top: individual time-shift distribution; bottom: group-wise boxplot of
the expected time-shift). Healthy individuals are generally displaced at the early stages of
the pathology, while the predictions for MCI and AD patients are associated with respec-
tively intermediate and late progression stages. NL: normal individuals, MCI: mild cognitive
impairment, AD: Alzheimer’s patients.
2.3.2. Model testing on de-novo individuals
The estimated probabilistic disease progression model provides a valuable
clinical reference, as it can be used to predict an individual pathological stage,
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as well as to quantify the biomarkers predictive value, or the influence of missing
data. To this end, we estimated the predictive performance of the model in290
assessing the individual pathological stage with respect to follow-up assessments
and missing biomarkers. This was done by estimating the predictive accuracy
of the group-wise separation obtained via increasing thresholds of the estimated
temporal progression.
3. Results295
3.1. Model plausibility
The estimated biomarker progression (Figure 1-A) shows a biologically plau-
sible description of the pathological evolution, compatible with previous findings
in longitudinal studies in familial AD [24], and with the hypothetical models of
AD progression [2, 25]. The progression is defined on a time scale spanning300
roughly 20 years, and is characterized at the initial stages by high-levels of
AV45, followed by the abnormality of ventricles volume, of FDG uptake, and of
the whole brain volume. These latter measures are however heterogeneously dis-
tributed across clinical groups, and with rather large variability. The evolution
is further characterized by increasing abnormality of the volumetric measures305
(especially hippocampal volume), and by the steady worsening of neuropsy-
chological scores such as FAQ. The model thus shows that the transition from
normal to pathological levels is essentially characterized by increase of hypo-
metabolism, followed by the pronounced temporal brain atrophy. Moreover,
the worsening of the neuropsychological and functional scores closely (almost310
linearly) follows the progression in the advanced clinical stages. The joint visual-
ization of the temporal progression of the biomarkers with temporal derivative
of the modelled average trajectories is shown in Supplementary figure A.10.
The illustration confirms that ADAS13 and FAQ are characterised by very sim-
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ilar longitudinal profiles, and show the largest changes in the latest stages of315
the pathology (peak of the derivative at t>0). On the contrary, the change
in hippocampal volume is more strongly associated with the earlier stages of
the pathology. AV45 and ventricles volumes are the least informative and are
associated with the lowest changes.
Figure 1-B (top) shows the posterior time-shift distributions associated with320
the individuals. The distributions denote the confidence of the model in asso-
ciating to each individual a temporal staging with respect to the global patho-
logical progression. The boxplot of Figure 1-B (bottom) reports the group-wise
expectation of the individual time-shifts. Healthy individuals (blue) are associ-
ated with the early stages of the pathology in both training and testing data,325
while MCI (purple) and AD patients (red) are characterized by respectively
intermediate and late predicted progression stages. The group-wise compari-
son between the expected time-shifts was statistically significant between each
group pairs (ANOVA, p <1e-6). Moreover, the time to conversion to AD in the
MCI group was significantly correlated with the disease staging quantified by330
the expectation of the individual time distributions (R2 = −0.4, p = 3.8e− 4).
Finally, when applying [8] to the training data we measured a strong agree-
ment between the resulting progression and the one obtained with our method,
resulting in a correlation between the corresponding individual time-shifts of
0.94 (p <1e-6) (Supplementary Material AppendixA.2.2).335
3.2. Assessing diagnostic uncertainty in testing data: an illustrative example.
This section illustrates the use of the model represented in Figure 1 for
the quantification of diagnostic uncertainty in testing individuals. We consider
the hypothetical scenario where the baseline values for different biomarkers are
measured for a given patient, namely FAQ, hippocampal and ventricle volumes.340
We assume that the biomarkers values correspond to the 20th percentiles with
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Figure 2: Illustrative example: posterior prediction of disease staging for a testing individual
based on baseline (left), and baseline + follow-up (right) information for three biomarkers:
FAQ, hippocampal and ventricles volume. The biomarkes values correspond to the 20th
and 50th percentiles of the training-group distribution for respectively baseline and follow-up
measures. Adding the follow-up information leads to increased estimates of the disease staging
and to generally lower prediction uncertainty. Although the distributions associated with
different biomarkers generally lead to similar expectations, FAQ and hippocampal volume lead
to the lowest diagnostic uncertainty. Vertical lines: expectation for each posterior distribution.
respect to the biomarkers distribution of the training set (i.e. FAQ = 1, nor-
malized Hippo = 5e-3, normalized Ventr = 1.7e-2). Figure 2 (left) shows the
disease staging prediction obtained with formula (8) based on the value of each
biomarker. We note that FAQ and hippocampal volume lead to similar poste-345
rior Gaussian distributions of disease staging, with expectation of respectively
tFAQ=-6 and thippo=-5.6 (indicated by the vertical lines in the figure), and stan-
dard deviation of sdFAQ=6.3 and sdhippo=5.9. The prediction associated with
ventricles volume is wider and associated with higher uncertainty, with mean
and standard deviation of respectively tventr=-3.8 and sdventr=6.1.350
We now suppose that for the same patient we acquire a follow-up measure-
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ment for each biomarker at year 1, with values corresponding to the 50th per-
centiles of the distribution of the training set (i.e. FAQ = 5, normalized Hippo
= 4.3e-3, normalized Ventr = 2.7e-2). The right hand side of Figure 2 shows
the new prediction based on the joint baseline+follow-up information. For each355
biomarker the posterior distributions indicate an increase of the predicted dis-
ease stage with respect to the baseline scenario, while the prediction uncertainty
is generally lower. Although the expectation for the 3 biomarkers is very simi-
lar (tFAQ=-2.5, thippo=-3.5, and tV entr=-3.2), we notice that FAQ leads to the
highest diagnostic confidence (sdFAQ=2.6), followed by hippocampal volume360
(sdHippo=3.8), and finally by ventricles volume (sdV entr=5.7). Further assess-
ment of the relationship between biomarker variability and model prediction is
provided in supplementary Section AppendixA.2.3.
This illustrative example shows that the proposed probabilistic framework
represents a valuable instrument for the assessment of the diagnostic value and365
uncertainty associated with different biomarkers, and can faithfully track the
pathological progression of testing individuals along the modeled trajectories,
from normal to pathological levels.
3.3. DPM for probabilistic diagnosis in ADNI.
We now assess the predictive results of the model when applied to the testing370
ADNI cohort. Figure 3 shows the individual posterior predictive distributions
associated with the testing individuals, and the boxplot of the expected time-
shift when using the model as statistical reference through formula (Figure 8).
The figure reports the two different modeling scenarios based on baseline infor-
mation only (Figure 3-1), and on the complete set of baseline and longitudinal375
measurements (Figure 3-2). We first note that the group-wise differences be-
tween the expected time-shifts are compatible for both scenarios, as shown by
the similar boxplot distributions across groups (Figure 3-1b vs 3-2b). The con-
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Figure 3: Posterior prediction for the individual time shift in testing data by using i) only the
baseline information (1a-b), and ii) the baseline + follow-up information available for each
testing subject (2a-b). Healthy individuals are generally displaced at the early stages of the
pathology, while the predictions for MCI and AD patients are associated with respectively
intermediate and late progression stages. The results are similar for both scenarios, although
by adding the follow-up information we largely reduce the uncertainty in the prediction of
the individual’s pathological stage (subfigure 1a vs 2a). NL: normal individuals, MCI: mild
cognitive impairment, AD: Alzheimer’s patients.
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sistency of the predictions is further illustrated in Figure A.9, where it is shown
that the group-wise distribution and ordering of the predicted time-shifts in the380
testing data are compatible with those estimated in the training one.
However, the joint use of baseline and follow-up information largely reduces
the uncertainty of the predictions (Figures 3-1a vs 3-2a). Indeed, the time distri-
butions predicted when using baseline and follow-up information are narrower
as compared to the wider confidence margins obtained by using the baseline385
information only. Therefore, adding follow-up measurements importantly im-
proves the confidence of the model in determining the individual pathological
stage.
As with the training case, for both scenarios the group-wise distribution
of the expected time-shift shows a significant separation between the clinical390
groups according to the increase of the pathological stage (ANOVA, p <1e-4).
Interestingly, the temporal positioning of the non converting MCI lies between
controls and MCI converters, and is on average lower than the one of healthy
individuals subsequently converted to cognitive impairment.
Figure 4 reports the classification results based on the baseline information395
only, and on increasing thresholds of the progression time course. Although
the model is not optimized to explicitly classify the clinical groups, the simple
thresholding based on the model predictions generally shows high face validity
with respect to the clinical diagnosis. For all the considered scenarios, the
highest accuracy is reached in a time window around the point t = 0, while the400
area under the ROC curve is .99, .88 and .83 for NL vs AD, MCI converters vs
MCI stable, and NL converters vs NL stable, respectively.
We further tested the model in presence of missing information, by com-
puting the predictions when only one baseline biomarker is available (Figure
5). The predictive outcomes show important variations depending on the con-405
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Figure 4: Predictive accuracy of the model when considering the joint set of available bio-
markers measurements. The vertical bar indicates the reference threshold value of t = 1.65,
corresponding to the 15th percentile of the time distribution of the training AD group. MCI:
individuals with mild cognitive impairment, AD: Alzheimer’s patients.
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sidered biomarker, while the confidence bounds for the predictions are usually
large, to denote increased uncertainty. We also note that FAQ, ADAS13, and
hippocampal volume are the biomarkers leading to the largest group-wise sepa-
ration, along with the lowest prediction uncertainty. This aspect is quantified in
Table 3, reporting the discrimination results with respect to the nominal cut-off410
point of t = 1.65, corresponding to the 15th percentile of the distribution of
the expected time-shift in the training AD group, as well as the area under the
receiving operating characteristic curve (AUC). Although the highest discrimi-
native results are consistently obtained when the biomarkers are used jointly, we
note that the neuropsychological tests generally lead to the best predictive per-415
formance in identifying AD patients with respect to healthy individuals, followed
by brain hypo-metabolism (FDG-PET), and temporal atrophy (Entorhinal and
Hippocampal volume). This is related to the lower uncertainty of the modelled
progressions, which leads to a more accurate identification of the individual
staging along the pathological trajectory. The scenario sensibly changes in the420
other comparison scenarios (MCI conv vs stable and NL conv vs stable), where
the sensitivity of the neuropsychological scores shows an important drop, while
the other biomarkers (especially hippocampal and entorhinal volumes) provide
comparable or even better discriminative performances.
These figures were similar when considering the single biomarkers within the425
longitudinal setting, where the neuropsychological tests still outperformed the
other biomarkers in discriminating the clinical groups (Supplementary Figure
A.11).
For the sake of comparison we finally benchmarked the predictive results
provided by the disease progression model with respect those obtained by the430
classification analysis performed with standard statistical tools, such as a ran-
dom forest classifier. We note that the comparison of the classification perfor-
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mance obtained on the heterogeneous data considered in this work is generally
challenging, since the proposed DPM 1) accounts for missing data and non-
fixed number of time points per individuals, and 2) is formulated in order to435
consistently handle both longitudinal and cross sectional measurements, either
for training and prediction. To date there is not a consensus on the optimal
approach to adopt to tackle these important modelling constraints, while the
comparison between the classification performance obtained with complex ma-
chine learning methods is currently matter of scientific debate and investigation440
[26].
For this reason we restricted the random forest classification task to a stan-
dard statistical setting, in order to essentially provide a reliable benchmark for
the classification performance of the proposed disease progression. To this end
we trained the random forest on the classification between healthy individuals445
and AD patients based on the baseline measurements of the training group,
while the missing entries in the testing data were imputed via nearest neigh-
bour search, based on the available biomarkers. The classification results are
reported in Supplementary Table A.5.
The performance of the random forest classifier is generally inferior to the450
one obtained with the proposed approach, as witnessed by the consistently lower
AUC obtained for all the comparisons. The difference becomes more evident for
the more challenging classification problems, such as the identification of conver-
sion in MCI and healthy individuals. This result is indicative of the reliability
of the classification results obtained by the proposed disease progression model,455
especially when considering that the random forest classifier is explicitly opti-
mized to maximize the separation between groups, while the accuracy results
reported in Table 3 are based on the empirical choice of a reference threshold
in the training population.
25
(a) Ventricles (b) WholeBrain (c) Entorhinal
(d) FDG (e) AV45 (f) RAVLT.learning
(g) FAQ (h) ADAS13 (i) Hippocampus
Figure 5: Posterior prediction on testing data by using a single biomarker and the baseline
information only.
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Biomarker
all Hippo Ventr WholeBr Entor FDG AV45 RAVLT FAQ ADAS13
NL vs AD (145 vs 74)
Accuracy .89 .81 .62 .76 .83 .80 .63 .82 .88 .83
Sensitivity .83 .84 .52 .9 .82 .74 .82 .76 .84 .75
Specificity .98 .76 .80 .46 .83 .89 .46 .94 .97 .98
AUC .99 .87 .69 .7 .89 .87 .73 .91 .98 .98
MCI conv vs MCI stable (106 vs 243)
Accuracy .82 .67 .62 .69 .7 .71 .69 .67 .79 .79
Sensitivity .65 .85 .5 .89 .74 .65 .37 .56 .63 .54
Specificity .90 .59 .68 .60 .68 .73 .75 .71 .86 .9
AUC .88 .79 .61 .78 .76 .74 .61 .66 .81 .82
NL conv vs NL stable (17 vs 74)
Accuracy .83 .70 .71 .54 .77 .76 .73 .83 .82 .83
Sensitivity .18 .47 .41 .82 .52 .29 .27 .35 .17 .17
Specificity .98 .77 .80 .47 .83 .89 .86 .94 .97 .98
AUC .83 .71 .65 .63 .74 .65 .65 .7 .63 .68
Table 3: Classification results by using the reference time threshold of t = 1.65, corresponding
to the 15th percentile of the training AD time distribution .
3.4. DPM staging and chronological age.460
We finally compare the relationship between the predicted disease staging
in training and testing set and the individual chronological age. We first note
that both training and testing clinical groups were matched by age, with the
exception of the 5 training healthy subjects converted to MCI (or AD) that were
slightly older with respect to the reference training healthy population (p=0.02).465
Nevertheless, when comparing the estimated time shift with respect to the
chronological age of each individual we didn’t report any significant correla-
tion between these measures. Interestingly, the same lack of association is also
quantifiable in the testing group (Figure 6). This result, in association with the
strong relationship between time shift and clinical condition reported in Section470
3.3, let us conclude that the model is describing the biomarker’s variation essen-
tially related to the pathological progression, which is orthogonal to the effect
of healthy aging quantified by the chronological age. This result points to the
effectiveness of the proposed approach in capturing significant effects related to
the specific temporal progression of the disease.475
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Figure 6: Chronological age (y-axis) vs model staging (x-axis). The estimated time-shift is
decorrelated from the chronological age in both training and testing data (p>0.05).
4. Discussion
This study explores the use of DPM for probabilistic diagnosis and uncer-
tainty quantification in an hypothetical clinical scenario. The proposed ap-
proach is based on the reformulation of DPM through a novel probabilistic ap-
proach aimed at leveraging on the longitudinal modeling of disease progression480
for prediction and quantification of the diagnostic uncertainty in neurodegen-
eration, by optimally combining the information provided by the several bio-
markers into a biologically plausible and intelligible score quantified by the time
shift. This work thus extends the previous contributions by proposing DPM as a
probabilistic tool for diagnostic purposes, which can be used to quantify staging485
and predictive uncertainty of de-novo individuals in clinical trials. The disease
progression model itself thus can be seen as a novel biomarker of pathological
progression. We also note that the time shift is a relative measure of disease
progression accounting for the biomarker variability observed in the training
population. Thus, the point 0 is generally not associated with the conversion to490
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AD, as it is relative to the data initialization (in this case the study baseline).
We illustrated the use of DPM as benchmarking tool for the statistical com-
parison of biomarkers. The model allows the quantification of the variability
associated with the single biomarkers, by identifying the related uncertainty in
characterizing the progression from normal to pathological levels. The proposed495
model can be thus used as a reference for screening and enrichment purposes in
clinical trials [27, 28, 29].
The modelled progression showed that neuropsychological tests generally
lead to lower uncertainty for identifying the individual clinical stage, and to
the higher separation power between healthy and AD groups. This finding is500
compatible with the results reported by previous disease progression models ap-
plied to ADNI, such as [7] and [15]. In this latter study ADAS13 consistently
appeared among the first events distinguishing the normal disease stages from
the pathological ones. Furthermore, our analysis further showed that volumetric
measures such as hippocampal and entorhinal volumes provide equivalent if not505
superior diagnostic performances when tested on the more challenging problem
of detecting conversion to dementia from healthy and MCI stages, especially in
terms of improved AUC. Nevertheless, some care should be taken in drawing
conclusions from the present analysis. Our model was based on the standard
volumetric measures provided in the ADNI database, and we cannot exclude510
that a more precise quantification of morphological brain changes would lead
to even better performance of volumetric biomarkers [30, 31]. Furthermore, the
proposed model was not optimized in order to maximize the classification accu-
racy between clinical groups. For example, the results reported in Table 3 are
based on the choice of the temporal threshold corresponding to the reference515
value of the 15th percentile of the AD distribution. This cut-off was not op-
timized to maximize the predictive outcome of the biomarkers, but was rather
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chosen based on heuristics aimed at illustrating the use of the model for predic-
tive purposes. We thus cannot exclude that the optimization of the temporal
threshold would lead to different figures for the classification task. The reported520
results are therefore indicative of the effectiveness of the model in faithfully rep-
resenting the clinical spectrum of the disease. We note also that the reported
figures are in line with those provided by state-of-art methods in AD classi-
fication, without requiring complex parameter optimization procedures, which
would introduce additional levels of cross-validation and expose the results to525
selection bias and generalization issues [26].
Thanks to the probabilistic formulation we showed that the use of longitudi-
nal information is important for reducing the uncertainty of the prediction, and
thus allowing one to better identify the disease status associated to an individ-
ual. This important aspect is in agreement with the generally higher statistical530
power reported in previous Alzheimer’s studies comparing longitudinal measure-
ments to baselines ones [32, 25, 33].
In this work we focused on the modelling of the progression of amyloid posi-
tive individuals. This choice was motivated by the interest in assessing the model
performance on an homogeneous clinical population likely to be representative535
of the Alzheimer’s evolution. While the absence of pathological amylod levels
seems indicative of non-Alzheimer’s pathophysiology [34, 35], there is currently
an active debate on the mechanisms of neurodegeneration not related to brain
amyloidosis [36]. The investigation of these aspects goes beyond the scope of the
present work, and future extensions of disease progression modeling will aim at540
identifying differential progressions underlying sub-pathologies, for example by
reformulating the proposed random effect regression within the realm of Gaus-
sian process mixture models [37, 38]. Analogously, the MCI population used
for model training was composed exclusively by MCI individuals subsequently
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converted to AD, in order to train the model on a homogeneous data most likely545
to include the largest representation of individuals effectively affected by Alzh-
eimer’s disease. Although the inclusion of MCI stable could provide additional
information on the intermediate pathological stages, this choice may probably
lead to larger variability in the training set, as stable MCI are generally charac-
terized by larger heterogeneity, either cross-sectionally and longitudinally, and550
higher diagnostic uncertainty. This modeling choice was also motivated by prac-
tical reasons since, thanks to the adopted data selection scheme, we were able
to validate the model on a large and independent set of testing individuals in-
cluding an important sample of MCI individuals across different clinical stages,
thus providing a thorough and stringent assessment of the predictive qualities555
of the proposed approach.
4.1. Methodological considerations
From the methodological perspective, we proposed a novel probabilistic ap-
proach based on Gaussian process regression for disease progression modeling
from time-series of biomarker measurements enabling novel applications beyond560
the state-of-art, such as the probabilistic prediction of disease staging in testing
individuals. Furthermore, the model naturally accounts for missing data, and
provides uncertainty quantification of the biomarker evolutions. Similarly to
[8], in this work we focused on the modeling of disease staging represented by
a time shift, although the proposed framework can naturally account for more565
complex time transformations, provided that a sufficient number of time points
is available for each individual.
From the methodological point of view, the proposed model extends current
approaches to GP-regression by consistently integrating time-reparameterization
and monotonic constraints within a random effect regression framework. Mono-570
tonic GPs were introduced in [20] as a principled regularization solution to im-
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prove the plausibility of modeling results. For example, the strength of such
a regularization approach in biomedical applications has been illustrated in
survival analysis [39]. Our approach extends this framework by consistently
integrating a latent time variable parameter within a random effect model for-575
mulation.
The idea of estimating a time transformation in a GP regression framework
has been previously used by [40] to account for uncertain measurement times to
a microarray dataset of mRNA. However, in that work the estimation of the time
uncertainty was subject to a strong prior constraint based on the assumption580
that the unknown biological time must be similar to the measured one. In
the application proposed in our work such an assumption is no longer valid and
would ultimately lead to implausible estimations. On the contrary, the proposed
GP regression is able to recover the underlying time transformation thanks to
the proposed monotonicity regularization.585
Finally, thanks to the flexibility of the proposed Gaussian process frame-
work, further extensions of the model will enable to consistently integrate a
spatio-temporal covariance model, such as the efficient Kronecker form of [41],
to provide a unified framework for jointly modelling time series of images and
scalar biomarkers data in a coherent fully Bayesian setting.590
5. Conclusions
This work proposes an extension of DPM for the accurate quantification
of the diagnostic uncertainty in Alzheimer’s disease. The proposed applica-
tion shows that DPM provides at the same time a plausible description of the
transition from normal to pathological stages along the natural history of the595
disease, as well as remarkable diagnostic performances when tested on de-novo
individuals. The model used in this study can account for any missing data
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patterns (longitudinal or across biomarkers), and allows to directly quantify the
uncertainty related to the missing information. It thus represents a novel and
promising tool for the analysis of clinical trials data.600
6. Further Information
The open-source code as well as the proposed predictive model trained on
ADNI data will be available at the author’s web-page: https://team.inria.
fr/asclepios/marco-lorenzi/. The realization of this study required about
1.5kWh of computing power.605
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AppendixA. Supplementary Information
AppendixA.1. Joint Model: marginal likelihood and inference
Given the sets of individual biomarker measurements y = {(yj(ti))k
j
i=1}Nj=1,
and of D control derivatives m = {mbk(t′l)}Dl=1 at points t′ = {t′l}Dl=1 for the
progression of each biomarker bk, the random effect GP model posterior is:
p
(
f , ḟ ,νj |y,m
)
=
1
Z
p(f , ḟ |t, t′)p(ν|t)p(y|f ,ν)p(m|ḟ)
= p(f , ḟ |t, t′)p(ν|t)p(y|f ,ν)∏
k
∏
l
Φ
(
1
λ
ḟbk(t
′
l)
)
, (A.1)
where ν = {νj}Nj=1. Thanks to the linearity of GPs under derivation, we
have that Cov
(
f(t), ḟ(t′)
)
= dCov(f(t),f(t
′))
dt′ , and that the joint distribution
p
(
f , ḟ |t, t′
)
is again a GP775
p
(
f , ḟ ,νj |t, t′
)
∼ GP (fjoint|0,Σjoint) ,
with fjoint =
f
ḟ
 distributed as
N

 0
0
 ,
 ΣG(f(t), f(t)) ∂ΣG(f(t),f(t′))∂t′
dΣG(f(t
′),f(t))
dt′
d2ΣG(f(t
′),f(t′))
dt′2

 .
AppendixA.1.1. Approximated inference
Due to the non-Gaussianity of the derivative likelihood term, the direct in-
ference on the posterior (A.1) is not possible due to its analytically intractable
form. For this reason, we employ an approximate inference scheme based on clas-780
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sical approaches to Gaussian process with binary activation functions [21]. Fol-
lowing [20], we compute an approximated posterior distribution q
(
f , ḟ ,νj |yj ,m
)
by replacing the derivative likelihood terms with local un-normalized Gaussian
approximations:
q
(
f , ḟ ,νj |yj ,m
)
=
1
ZEP
p(f , ḟ |t, t′)p(ν|t)p(y|f ,ν)∏
k
∏
l
Z̃klN (ḟbk(t′l)|µ̃kl, σ̃2kl), (A.2)
where ∏
k
∏
l
Z̃klN (ḟbk(t′l)|µ̃kl, σ̃2kl) = N (µ̃, Σ̃)
∏
k,l
Z̃kl,
with µ̃ = [µ̃kl], and Σ̃ is a diagonal matrix with elements σ̃2kl. It follows that785
the marginal posterior has a Gaussian form, q
(
f , ḟ ,νj |yj ,m
)
∼ N (µ,Σ), with
µ = ΣΣ̃−1µ̃joint , and Σ = (Σ
−1
joint + Σ̃
−1
joint)
−1, where
µ̃joint =
y
µ̃
 , and Σ̃joint =
 Σε + ΣS 0
0 Σ̃
 .
AppendixA.1.2. Estimating the EP parameters.
The EP update of the local Gaussian approximation parameters is classically
done by iterative moment matching with respect to the product between the cav-790
ity distributions q−k′l′
(
ḟbk′ (t
′
l′)
)
and the target likelihood term Φ
(
1
λ ḟbk′ (t
′
l′)
)
.
In the GP case the cavity distribution has a straightforward Gaussian form:
q−k′l′
(
ḟbk′ (t
′
l′)
)
=
∫ ∏
k 6=k′,
l 6=l′
Z̃klN (ḟbk(t′l)|µ̃kl, σ̃2kl)dḟbk(t′l)
∼ N (ḟbk′ (t
′
l′)|µ−k′l′ , σ−k′l′). (A.3)
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As shown in [20] for univariate monotonic regression, moments and updates
of the approximation parameters can be computed in an analogous manner as
in the classical GP classification problem [19].795
AppendixA.1.3. Marginal Likelihood and hyper-parameter estimation
The model’s log-marginal likelihood under the EP approximation is:
logL = −1
2
log |Σjoint + Σ̃joint|
−1
2
µ̃Tjoint(Σjoint + Σ̃joint)
−1µ̃joint
+
∑
k
∑
l
(µ−kl − µ̃kl)2
2(σ2−kl) + σ̃
2
kl)
+
∑
k
∑
l
log Φ(
µ−kl√
λ2k + σ
2
−kl)
)
+
1
2
∑
k
∑
l
log(σ2−kl + σ̃
2
kl). (A.4)
In what follows, the optimal parameters are obtained by maximising logL
through conjugate gradient descent, via alternate optimization between the
hyper-parameters θG and θ
j
G, and the individuals’ time-shifts d
j . The posi-800
tion of the derivative points was updated at each iteration, according to the
changes of the GP domain. Regularisation was also enforced by introducing
Gaussian priors for the parameters θG and θ
j
G. We note that the block struc-
ture of the GP covariance allows the computation of the gradients with respect
to the biomarkers’ and individual parameters by working on matrices of much805
smaller dimension than the one of the whole GP, thus considerably improv-
ing the numerical stability and the computational efficiency of the optimization
procedure.
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AppendixA.2. Model benchmarking on synthetic multivariate progressions
We benchmarked the model with respect to synthetic multivariate biomarker810
progressions. We generated random multivariate sigmoid functions for Nb bio-
markers, f(τ) = (fb1(τ), fb2(τ), . . . , fbNb (τ))
>, with fbk(τ) = 1/(1+exp(−αkτ)),
τ ∈ [0, 15] and αk ∼ N (0, .06), and we sampled N individual noisy trajectories
at time points τ jk : y
j
k(τ
j
k) = fk(τ
j
k) + ε, ε ∼ N (0, σ2). For each individual we
used the same initial sampling time point for every biomarker, while the num-815
ber of samples per biomarker was allowed to independently vary between 1 and
4. The individual time points were subsequently centered by their mean µjk to
obtain shifted time-points tjk = τ
j
k − µ
j
k defined in the interval [−2, 2].
The model was applied to estimate biomarker progressions and individual
time-shifts with respect to different combinations of trajectory noise σ, sample820
size N , and number of biomarkers Nb. The accuracy of the model in recon-
structing the original time series was quantified by Pearson’s correlation be-
tween the estimated time-shift dj and the original individual time reference.
The experiments were repeated 10 times for each configuration of parameters
σ ∈ {0.1, 0.2, 0.3, 0.4}, Nb ∈ {4, 8}, and N ∈ {20, 100}.825
AppendixA.2.1. Results.
Table A.4 reports summary correlations between time-shift estimation and
the ground truth individual sampling time. The correlation values are generally
high, and increase with lower noise levels. Interestingly, the increase in number830
of modelled biomarkers is associated with a better performance in recovering
the underlying disease staging. We also observe that larger sample sizes are
associated with higher correlation values, especially with increasing noise levels.
We note however an exception for the case σ = 0.1 where, although the overall
performance is still high, the correlation slightly decreases with N = 100.835
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N = 20 N = 100
σ σ
0.1 0.2 0.3 0.4 0.1 0.2 0.3 .4
Nb
4 .95 (.03) .86 (.08) .71 (.17) .46 (.29) .91 (.04) .89(.04) .76 (.17) .75 (.12)
8 .97 (.01) .91 (.06) .86 (.06) .66 (.3) .94 (.04) .94 (.02) .88 (.06) .84 (.07)
Table A.4: Mean (sd) R2 correlation coefficient across folds between estimated individual
time-shifts and ground truth time reference.
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AppendixA.2.2. Model benchmarking with respect to grace
The R package grace (v 1.0) was used to estimate the multivariate biomarker
progression curves from the training set used in this study, by using default pa-
rameters and syntax:
grace . s imu la t i on . f i t s <− with ( output_table , . . .840
grace (Month , Y, Outcome , RID , group , p l o t s = TRUE) )
Figure A.7 shows the relationship between the estimated individual time-
shift. Although the time range estimated by the GP model is roughly double
with the respect to the grace one, there is a strong agreement between the
relative positioning of the training individuals along the disease trajectory.845
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Figure A.7: Comparison between the shift estimated with our GP progression model (x-
axis), and the one estimated by grace (y-axis). Although the time range estimated by the
GP model is roughly double with the respect to the grace one, there is a strong agreement
between the relative positioning of the training individuals along the disease trajectory.
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AppendixA.2.3. Predictive performance under uncertain biomarker distribution
In this section we illustrate the relationship between the variability across
an individual’s biomarkers profile at a given time point and the subsequent time
shift estimation. This point is tested in the following synthetic cases, where we
considered three hypothetical baseline scenarios:850
1. Homogeneous, low severity: all the biomarkers measurements for the
individual correspond to the 10th percentile of the respective distribution
2. Homogeneous, high severity: all the biomarkers measurements for the
individual correspond to the 90th percentile of the respective distribution
3. Heterogeneous: all the biomarkers measurements for the individual cor-855
respond to the 10th percentile of the respective distribution, while FAQ
and ADAS are at the 90th percentile.
Figure A.8 illustrates the resulting log-likelihood of the prediction. We can see
that for the homogeneous scenarios (blue and red curve), the log-likelihood is
high and concentrated on the left and right extremities of the time axis, to in-860
dicate indeed greater confidence about low and high severity of the individual.
On the contrary, the heterogeneous case (green curve) is characterized by (mag-
nitude) lower log-likelihood values, and by an almost uniform profile across the
time axis, to indicate higher uncertainty about the staging prediction.
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Figure A.8: Predictive uncertainty with respect to individual’s biomarkers variability
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AppendixA.2.4. Supplementary Figure865
Figure A.9: Comparison between the time shift distribution in training and testing data.
The group-wise distribution and ordering of the predicted time-shifts in the testing data are
compatible with those estimated in the training one.
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Figure A.10: Joint temporal progression of the biomarkers (top) and derivative of the mod-
elled average trajectory (bottom). ADAS13 and FAQ are characterised by very similar longi-
tudinal profiles, and show the largest changes in the latest stages of the pathology (peak of
the derivative at t>0). On the contrary, the change in hippocampal volume is more strongly
associated with the earlier stages of the pathology. AV45 and ventricles volumes are the least
informative and are associated with the lowest changes (lowest derivative values).
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AppendixA.2.5. Supplementary Table
(a) Ventricles (b) WholeBrain (c) Entorhinal
(d) FDG (e) AV45 (f) RAVLT.learning
(g) FAQ (h) ADAS13 (i) Hippocampus
Figure A.11: Posterior prediction on testing data by using a single biomarker and the follow-up
information.
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NL vs AD (145 vs 74) MCI conv vs MCI stable (106 vs 243) NL conv vs NL stable (17 vs 74)
Accuracy .95 .69 .86
Sensitivity .94 .89 .28
Specificity .97 .61 .97
AUC .96 .75 .62
Table A.5: Classification results by using a random forest classifier trained on the whole set of
biomarkers for the baseline training data. The missing values in the testing data were imputed
by nearest neighbour search.
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AppendixA.2.6. Data preparation
#Loading ADNIMERGE l i b r a r y
870
l i b r a r y ("ADNIMERGE")
#Id en t i f y i n g c l i n i c a l subgroups
ridAD = unique ( subset ( adnimerge ,DX=="Dementia ")$RID)875
ridNL = unique ( subset ( adnimerge ,DX=="NL")$RID)
ridMCI = unique ( subset ( adnimerge ,DX=="MCI")$RID)
#In the next s t ep s converted / r eve r t ed i nd i v i d u a l s are manually i d e n t i f i e d
# and c l i n i c a l groups are de f ined acco rd ing ly880
ADreverted = c (167 , 1226 , 4641)
ridAD = ridAD [ ! ridAD%in%ADreverted ]
NLconverted = c (15 , 22 , 35 , 55 , 61 , 106 , 112 , 127 , 156 , 171 , 210 , 223 , 232 ,885
259 , 420 , 454 , 459 , 467 , 520 , 545 , 548 , 555 , 558 , 602 , 605 , 622 , 680 , 722 ,
778 , 779 , 842 , 843 , 883 , 899 , 920 , 972 , 985 , 1063 , 1123 , 1169 , 1190 , 1194 ,
1200 , 1202 , 1203 , 2150 , 4041 , 4071 , 4092 , 4218 , 4262 , 4385 , 4474 , 4506 , 4566 ,
4577 , 4579 , 4652 , 4855 , 5096 , 5121 , 5207 , 5273)
ridNL = ridNL [ ! ridNL%in%NLconverted ]890
ridConv = subset ( adnimerge ,RID%in%ridMCI&DX=="MCI to Dementia ")$RID
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r i dReve r t e r = c (429 , 4706)
ridConv = ridConv [ ! ridConv%in%r idReve r t e r ]895
ridMCI = c ( ridMCI , ADreverted )
ridNConv = ridMCI [ which ( ! ridMCI%in%ridConv ) ]
ridNConv = ridNConv [ ! ridNConv%in%c ( ridConv , ridAD , ridNL , NLconverted ) ]
900
ridAD = ridAD[−which ( ridAD%in%ridConv ) ]
#Amyloid p o s i t i v e i n d i v i d u a l s are r e t a in ed f o r subsequent an a l y s i s
905
Abpos = read . csv ("AbposADNI . csv " , sk ip=1)
ridABpos = Abpos$RID
Set = subset ( adnimerge ,RID%in%c ( ridNConv , ridConv , ridAD , ridNL , NLconverted ) ,
s e l e c t=c ("RID" ,"Month" ,"DX" ,"Hippocampus " ,910
" Ven t r i c l e s " ,"WholeBrain " ," Entorh ina l " ,"FDG" ,"AV45" ,
"RAVLT. l e a rn i ng " ,"FAQ" , "ADAS13" ,"ICV . b l " ) )
#Brain volumes are s c a l ed f o r ICV
915
Set$Hippocampus = Set$Hippocampus/Set$ICV . b l
Set$WholeBrain = Set$WholeBrain/Set$ICV . b l
Set$Entorh ina l = Set$Entorh ina l /Set$ICV . b l
S e t $Ven t r i c l e s = Se t $Ven t r i c l e s /Set$ICV . b l
920
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Set = subset ( Set , s e l e c t=c ("RID" ,"Month" ,"DX" ,"Hippocampus " ," Ven t r i c l e s " ,
"WholeBrain " ," Entorh ina l " ,"FDG" ,"AV45" , "RAVLT. l e a rn i ng " ,"FAQ" , "ADAS13") )
#Id en t i f y i n g i n d i v i d u a l s with at l e a s t one measurements f o r each biomarker
# ( t r a i n i n g s e t )925
RIDnoNA = subset ( Set ,Month==0)$RID [ which ( apply ( i s . na ( subset ( Set ,Month==0)) ,
1 , any)==FALSE) ]
SetnoNA = subset ( Set ,RID%in%ridABpos&RID%in%RIDnoNA&RID%in%930
c ( ridConv , ridAD , ridNL , NLconverted ) )
#Sampling t r a i n i n g s e t composed by 200 i nd i v i dua l s , and t e s t i n g s e t composed by
#remaining ones
935
trainRID = sample ( unique (SetnoNA$RID ) ,200)
t r a i nS e t = subset ( Set ,RID%in%trainRID )
t e s t S e t = subset ( Set , ! RID%in%trainRID&RID%in%Abpos$RID)
#Ranking o f biomarkers va lue s accord ing to940
# tra i n i n g s e t d i s t r i b u t i o n
newSet = t r a i nS e t
945
f o r ( i in seq (4 , l ength ( names ( newSet ) ) ) )
{
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newSet [ , i ] = rank ( newSet [ , i ] , na . l a s t =’keep ’ ) /
l ength ( newSet [ , i ] [ which ( ! i s . na ( newSet [ , i ] ) ) ] )
}950
newSet_test = t e s t S e t
955
f o r ( i in seq (4 , l ength ( names ( newSet ) ) ) ) {
f o r ( j in seq (1 , l ength ( newSet_test [ , i ] ) ) )
{
i f ( ! i s . na ( t e s t S e t [ j , i ] ) )
{960
newSet_test [ j , i ] = rank ( c ( t e s t S e t [ j , i ] , t r a i nS e t [ , i ] ) ,
na . l a s t =’keep ’ ) [ 1 ] /
( l ength ( t r a i nS e t [ , i ] [ which ( ! i s . na ( t r a i nS e t [ , i ] ) ) ] )+1 )
}
965
}
}
# Sca l i ng the biomarkers to i n c r e a s i n g abnormal ity order970
newSet$FDG = 1−newSet$FDG
newSet$Hippocampus = 1−newSet$Hippocampus
newSet$WholeBrain = 1−newSet$WholeBrain
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newSet$Entorhinal = 1−newSet$Entorhinal975
newSet$RAVLT . l e a rn i ng = 1 − newSet$RAVLT . l e a rn i ng
newSet_test$FDG = 1−newSet_test$FDG
newSet_test$Hippocampus = 1−newSet_test$Hippocampus
newSet_test$WholeBrain = 1−newSet_test$WholeBrain980
newSet_test$Entorhinal = 1−newSet_test$Entorhinal
newSet_test$RAVLT . l e a rn i ng = 1 − newSet_test$RAVLT . l e a rn i ng
# Output985
wr i t e . csv ( newSet , " ADNIDataTrain . csv ")
wr i t e . csv ( newSet_test , " ADNIDataTest . csv ")
wr i t e . csv ( ridAD ," ridAD . csv " , row . names=FALSE)990
wr i t e . csv ( NLconverted , " ridNLconverted . csv " , row . names=FALSE)
wr i t e . csv ( ridConv , " ridConv . csv " , row . names=FALSE)
wr i t e . csv ( ridNL ," ridNL . csv " , row . names=FALSE)
wr i t e . csv ( ridNConv [ ridNConv%in%ridABpos ] , " ridNConv . csv " , row . names=FALSE)
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